Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Radiotherapy
78%
Head-and-neck Cancer
69%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
67%
Radiation Therapy
56%
Overall Survival
48%
National Cancer Database
36%
Hazard Ratio
32%
Tumor
31%
95% Confidence Interval
30%
Stereotactic Body Radiation Therapy
28%
EphrinB2
23%
Tumor Growth
23%
Treg
23%
Survival Outcomes
22%
Tumor Microenvironment
20%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
19%
Cancer-specific Survival
19%
Pancreatic Ductal Adenocarcinoma
17%
EphB4
16%
Neck Tumor
15%
Chemoradiotherapy
14%
Metastasis
14%
Squamous Cell Carcinoma (SqCC)
14%
Non-small Cell Lung Cancer (NSCLC)
14%
Chemotherapy
14%
Elderly Patients
14%
Odds Ratio
13%
Pancreatic Cancer
13%
Cancer Cells
13%
In Cancer
12%
Medulloblastoma
12%
Durvalumab
12%
Improved Survival
12%
Squamous Carcinoma Cells
12%
Local Control
11%
Patients with Cancer
11%
EphA4
11%
United States
11%
Regulatory T Cells
10%
Locally Advanced
10%
Larynx Cancer
10%
Oral Tongue Squamous Cell Carcinoma (OTSCC)
10%
CD8 T Cells
10%
Cetuximab
10%
Knockdown
10%
Propensity Score Matching
10%
Stereotactic Body Radiotherapy
10%
Orthotopic Model
9%
Response to Radiation
9%
Natural Killer Cells
9%
Medicine and Dentistry
Radiation Therapy
100%
Malignant Neoplasm
63%
Head and Neck Cancer
58%
Overall Survival
53%
Diseases
42%
Stereotactic Body Radiation Therapy
40%
Hazard Ratio
32%
Chemoradiotherapy
30%
Chemotherapy
29%
Cancer
28%
Head and Neck Squamous Cell Carcinoma
26%
Neoplasm
25%
Non Small Cell Lung Cancer
25%
Tumor
23%
Immunotherapy
21%
Cancer Specific Survival
17%
Base
17%
Pancreas Cancer
16%
Squamous Cell Carcinoma
16%
Laryngeal Cancer
15%
Oropharynx Carcinoma
14%
Elderly Patient
14%
Odds Ratio
13%
Median Follow Up
13%
Pancreas Adenocarcinoma
13%
Cetuximab
12%
Medicare
11%
Proportional Hazards Model
11%
Cancer Therapy
11%
Radiosurgery
11%
Progression Free Survival
10%
Immune Response
9%
Propensity Score Matching
9%
Tumor Progression
9%
Durvalumab
9%
Neoadjuvant Chemotherapy
9%
Melanoma
9%
Treatment Modality
9%
Multivariate Analysis
8%
Computer Assisted Tomography
8%
Oropharynx Squamous Cell Carcinoma
8%
Surveillance, Epidemiology, and End Results
8%
Positron Emission Tomography
7%
Ephrin B2
7%
Biological Marker
7%
Treatment Outcome
7%
Clinical Trial
7%
Oral Cavity
7%
Recurrent Disease
7%
Intensity Modulated Radiation Therapy
7%